Effects of rilpivirine on human adipocyte differentiation, gene expression, and release of adipokines and cytokines

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3369-3375

  Díaz Delfín, Julieta ^a   Domingo, Pere ^b   Mateo, Maria Gracia ^b   Gutierrez, Maria Del Mar ^b   Domingo, Joan Carles ^a   Giralt, Marta ^a   Villarroya, Francesc ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ANTIRETROVIRUS AGENT; CCAAT ENHANCER BINDING PROTEIN ALPHA; CYTOCHROME C OXIDASE; CYTOCHROME C OXIDASE II; CYTOCHROME C OXIDASE IV; CYTOKINE; EFAVIRENZ; INTERLEUKIN 6; INTERLEUKIN 8; LEPTIN; LIPOPROTEIN LIPASE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; NERVE GROWTH FACTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; RILPIVIRINE; SCATTER FACTOR; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOGENESIS; ADIPOSE TISSUE; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG EFFECT; DYSLIPIDEMIA; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; INFLAMMATION; LIPID METABOLISM; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN EXPRESSION; PROTEIN SECRETION; SIDE EFFECT;

ADIPOCYTES; ADIPOKINES; ANTI-HIV AGENTS; BENZOXAZINES; CCAAT-ENHANCER-BINDING PROTEIN-ALPHA; CELL DIFFERENTIATION; CELLS, CULTURED; CYTOKINES; GENE EXPRESSION; HUMANS; NITRILES; PPAR GAMMA; PYRIMIDINES; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

EID: 84861145431     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00104-12     Document Type: Article

References (26)

1. Bell LN, et al. 2008. A central role for hepatocyte growth factor in adipose tissue angiogenesis. Am. J. Physiol. Endocrinol. Metab. 294:E336-E344. (Pubitemid 351231459)
2. Bulló M, Peeraully MR, Trayhurn P, Folch J, Salas-Salvadó J. 2007. Circulating nerve growth factor levels in relation to obesity and the metabolic syndrome in women. Eur. J. Endocrinol. 157:303-310. (Pubitemid 47603534)
3. Cohen CJ, et al. 2011. Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet 378:229-237.
4. Crauwels HM, et al. 2010. Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naive, HIV-1-infected patients in ECHO and THRIVE. J. Int. AIDS Soc. 13(Suppl 4):P186.
5. Crauwels H, Vingerhoets J, Ryan R, Witek J, Anderson D. 9 November 2011. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir. Ther. [Epub ahead of print.] doi:10.3851/IMP1959.
6. de Bethune MP, et al. 2005. TMC278, a new potent NNRTI with an increased barrier to resistance and favourable pharmacokinetic profile, abstr 556. Abstr. 12th Conf. Retroviruses Opportunistic Infect.
7. Díaz-Delfín J, et al. 2011. Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 91:112-119.
8. Dupin N, et al. 2002. HIV and antiretroviral drug distribution in plasma and fat tissue of HIV-infected patients with lipodystrophy. AIDS 16:2419-2424. (Pubitemid 35471689)
9. El Hadri K, et al. 2004. In vitro suppression of the lipogenic pathway by the nonnucleoside reverse transcriptase inhibitor efavirenz in 3T3 and human preadipocytes or adipocytes. J. Biol. Chem. 279:15130-15141. (Pubitemid 38618908)
10. Gallego-Escuredo JM, et al. 2010. Differential effects of efavirenz and lopinavir/ritonavir on human adipocyte differentiation, gene expression and release of adipokines and proinflammatory cytokines. Curr. HIV Res. 8:545-553.
11. Gazzard BG, et al. 2008. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy. HIV Med. 9:563-608.
12. Goebel F, et al. 2006. Short-term antiviral activity of TMC278 - a novel NNRTI - in treatment-naive HIV-1-infected subjects. AIDS 20:1721-1726. (Pubitemid 44299363)
13. Hammer SM, et al. 2008. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-U.S.A. panel. JAMA 300:555-570.
14. Haubrich RH, et al. 2009. AIDS Clinical Trials Group (ACTG) A5142 Study Team. Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS 23:1109-1118.
15. Janssen PA, et al. 2005. In search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2- cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine). J. Med. Chem. 48:1901-1909. (Pubitemid 40396320)
16. Kadowaki T, et al. 2006. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J. Clin. Invest. 116: 1784-1792. (Pubitemid 44033298)
17. Molina JM, et al. 2011. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1(ECHO):a phase 3 randomised double-blind active-controlled trial. Lancet 378:238-246.
18. Pérez-Molina JA, Domingo P, Martínez E, Moreno S. 2008. The role of efavirenz compared with protease inhibitors in the body fat changes associated with highly active antiretroviral therapy. J. Antimicrob. Chemother. 62:234-245. (Pubitemid 351984766)
19. Riddler SA, et al. 2008. AIDS Clinical Trials Group Study A5142 Team. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358:2095-2106. (Pubitemid 351679596)
20. Schlüter A, Yubero P, Iglesias R, Giralt M, Villarroya F. 2002. The chlorophyll-derived metabolite phytanic acid induces white adipocyte differentiation. Int. J. Obes. Relat. Metab. Disord. 26:277-1280.
21. Stankov MV, Behrens GM. 2010. Contribution of inflammation to fat redistribution and metabolic disturbances in HIV-1 infected patients. Curr. Pharm. Des. 16:3361-3371.
22. Staszewski S, et al. 1999. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N. Engl. J. Med. 341:1865-1873.
23. Tebas P, et al. 2011. Results from the pooled DEXA substudies of the double-blind, randomised, phase III trials comparing rilpivirine (RPV, TMC278) versus efavirenz (EFV) in treatment-naïve, HIV-infected adults. Antivir. Ther. 16(Suppl 2):A19.
24. U. S. Food and Drug Administration. 2011. Approval of Edurant, rilpivirine, a new NNRTI for the treatment of HIV in treatment naive patients. FDA, Washington, DC. http://www.fda.gov/ForConsumers/ByAudience/ ForPatientAdvocates/HIVandAIDSActivities/ucm256151.htm.
25. Villarroya F, Domingo P, Giralt M. 2007. Lipodystrophy in HIV 1-infected patients: lessons for obesity research. Int. J. Obes. (Lond.) 31:1763-1776. (Pubitemid 350174633)
26. Wilkin A, et al. 2012. Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. AIDS Res. Hum. Retrovir. 28:437-446.